Business Wire

Mary Kay Inc. Advocates for Women’s Empowerment, Safe and Dignified Work Environments at International Women’s Forum – TIME’S UP UK Virtual Event

22.7.2020 15:00:00 EEST | Business Wire | Press release

Share

On May 21st, Mary Kay Inc., an advocate for global women’s empowerment and entrepreneurship, joined the International Women's Forum (IWF) Virtual Conference, for a session titled “SAFE SETS: An online panel discussion with TIME’S UP UK.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200722005187/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Carolyn Passey, General Manager, Mary Kay United Kingdom & Ireland (Photo: Mary Kay Inc.)

The live session tackled the ever-present issue for women across the globe: sexual harassment and abuse in the workplace. TIME’S UP UK stressed the critical importance of changing the culture to ensure a safe workplace free from harassment and referred to the work being done to define safety for women in film through intimacy guidelines.

The speakers with TIME’S UP UK included:

  • Dame Heather Rabbatts, TIME’S UP UK Chair, Managing Director of Cove Pictures; Chair of Soho Theatre and non-executive board member for Arts Alliance.
  • Ita O’Brien, the UK’s leading Intimacy Coordinator and founder of Intimacy on Set, her company through which she has been developing best practices regarding intimacy and nudity in film, television and theatre and through which she trains Intimacy Coordinators all over the world.

“TIME’S UP’s efforts will help bring about broader change for women in the workplace – worldwide and across industries,” said Carolyn Passey, General Manager of Mary Kay UK and Ireland. “As one of the world’s leading champions of women’s empowerment, Mary Kay is proud to support, through IWF, women leaders who are standing up to give fellow women a voice, help them embrace their identity and define their own boundaries.”

“What was increasingly apparent throughout the conversation was how #MeToo and TIME’S UP have had a huge and positive influence for changing the way productions work, how they are shifting to better practices in many new ways, and in particular with the new role of the Intimacy Coordinator,” said Dame Heather Rabbatts. “The conversation about safe sets is about how we make the culture shift, one industry after another, until we don’t need to have this conversation ever again.”

“‘Yes’, means yes, ‘no’ means no, and ‘maybe’ means no – we celebrate and embrace the ‘no’,” emphasized Ita O’Brien, when talking of the process during which actors get to voice their comfort level when shooting intimate scenes. The firm founded by O’Brien, Intimacy on Set, has put in place guidelines to provide clear lanes of communication and consent not only between actors, but also everyone else involved in shooting intimate and emotional scenes. “Clear boundaries actually create freedom and help understand what is right for you.”

“This line goes to the heart of the matter, and how we are all learning to express where our boundaries lie, and not being afraid to share them,” concluded Dame Heather Rabbatts. “Having in place some mechanisms to protect yourself is very important, so that we know we can exercise a ‘no’. This should empower us in all the sticky and difficult situations that happen in life, whether personal or professional.”

“It is invigorating to witness the influential work that female thought leaders and advocates have achieved over the past several years for the advancement of women’s safety and security in the workplace. These women, some of the most influential thought leaders in the United Kingdom, are on a mission to champion the next generation of women to become tomorrow’s leaders,” said Marty Wikstrom, Member of IWF U.K. and co-chair of the Cornerstone Conference. “IWF has been advancing women’s leadership and championing equality worldwide since 1974, and Mary Kay has been an advocate of women’s entrepreneurship and leadership since 1963. This session reflects a meeting of the minds, and we are proud to showcase this female-fueled partnership.”

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 56 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at MaryKay.com.

About International Women’s Forum (IWF) and the Leadership Foundation

IWF is an invitation-only membership organization of more than 7,000 diverse and accomplished women from 33 nations on six continents. IWF advances women’s leadership and champions equality worldwide by connecting accomplished women both globally and locally. Members include Fortune 500 executives, government leaders from the local to sovereign level, international nonprofit leaders, and luminaries from the academy, arts and sciences: www.iwforum.org.

About TIME’S UP UK

TIME’S UP is an organisation that insists on safe, fair and dignified work for women of all kinds. In response to the growing TIME’S UP movement in the US, a group of UK-based women: actors, producers, writers and others from the film, TV and theatre industries catalysed a sister initiative in the UK. For maximum impact it is set up under the TIME’S UP brand and aims to amplify and reinforce the message already promoted in the US.

The UK movement seeks to build on key elements of the solidarity letter released by TIME’S UP and the statement by the activists attending the Globes, which emphasised the need to highlight the connections between the harassment revelations in Hollywood and the wider, systematic nature of harassment and violence against women across all industries, contexts and countries with the recognition that this issue is universal. We seek strength in unity and maximum cooperation. The activist statement also flagged the ways in which the TIME’S UP initiative joins an ever-growing collective of organisations, movements and leaders working to end gender-based violence. The UK work stands absolutely in solidarity with existing movements: TIME’S UP UK is also now a recently formed charity, and as a charity we can only continue the work with support and donations. We all appreciate that we are experiencing unprecedented challenges but as TIME’S UP focusses on safety for all women in the workplace, which now includes the home, we hope you will be able to support us: www.timesupuk.org.

About Intimacy on Set

Founded in 2018, Intimacy on Set provides services to TV, film, & theatre when dealing with intimacy, sexual content, and nudity. Its Founder, UK’s leading Intimacy Coordinator, Ita O’Brien, pioneered the role of the Intimacy Coordinator and since 2014 has been developing best practice Intimacy on Set Guidelines, which have been widely adopted in the industry. Championed by the TIME’S UP movement and others, the firm advocates for safe, fair and dignified work for everyone. O’Brien has worked on numerous high profile productions including Normal People (BBC3/Hulu), Sex Education 1&2 (Netflix), Gangs of London (Sky Atlantic), The Great (Hulu) and I May Destroy You (BBC/HBO), and has been widely covered in the national and international media as the leading spokesperson in this space: www.intimacyonset.com/.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mary Kay Inc. Corporate Communications
marykay.com/newsroom
972.687.5332 or media@mkcorp.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye